The expansion is related to a new market that Boston Scientific expects to enter in a matter of weeks—drug-coated stents. The Natick, MA-based company is on the verge of getting approval from the federal Food and Drug Administration to sell the Taxus stent in the US. Many Wall Street analysts predict Boston Scientific could quickly dominate the market. They also expect the overall market segment could soon grow to $5 billion next year.
FDA Inspectors arrived this week to visit Boston Scientific's operations in the Twin Cities—one of the final steps in the process to approve its new drug-coated stent. The company could get approval in the next two to six weeks, says Thomas Gunderson, a securities analyst with U.S. Bancorp Piper Jaffray.
© Touchpoint Markets, All Rights Reserved. Request academic re-use from www.copyright.com. All other uses, submit a request to asset-and-logo-licensing@alm.com. For more inforrmation visit Asset & Logo Licensing.
